Core Viewpoint - Dongguan Dingtong Precision Technology Co., Ltd. is planning a pre-IPO share transfer through a non-public inquiry transfer, with a total of 4,176,000 shares, representing 3.00% of the company's total equity [2][7]. Group 1: Share Transfer Details - The transferring shareholder is Dongguan Dinhong Junsheng Investment Co., Ltd., which is the controlling shareholder of Dingtong Technology [3]. - The shares being transferred have been released from restrictions and are free of any transfer limitations [3][5]. - The transfer is motivated by the shareholder's need for funds [7]. Group 2: Transfer Pricing and Conditions - The minimum transfer price will not be lower than 70% of the average trading price over the 20 trading days prior to July 31, 2025 [8]. - If the total valid subscriptions exceed the number of shares available, the transfer price will be determined based on price priority, quantity priority, and time priority [9]. - The transfer is open to institutional investors with appropriate pricing capabilities and risk tolerance [10].

Core Viewpoint - The equity transfer by major shareholders of Suzhou Yubang New Material Co., Ltd. (Yubang New Material) involves a reduction in their shareholding from 60.52% to 58.25%, which does not change the control of the company or its governance structure [1][6][12]. Group 1: Shareholder Transfer Details - The transfer involved 2,500,000 shares at a price of 31.02 yuan per share, totaling 77,550,000 yuan [2][10]. - The transferring party, Suzhou Yuzhi Partner Enterprise Management (Limited Partnership), is a major shareholder and acted in concert with Suzhou Juxinyuan Enterprise Management Co., Ltd., and individuals Xiao Feng and Lin Min [3][6]. - The transfer was executed through a price inquiry method and does not trigger a mandatory tender offer [1][12]. Group 2: Shareholding Structure - Following the transfer, the combined shareholding of the transferring party and its concerted actors decreased to 58.25% of the total share capital [4][6]. - The shareholding structure before the transfer included 56,500,000 shares held by Suzhou Juxinyuan, 4,125,000 shares by Xiao Feng, and 3,375,000 shares by Lin Min, totaling 66,500,000 shares or 60.52% [8][10]. Group 3: Regulatory Compliance - The transfer process adhered to relevant regulations, including the Securities Law and the Shenzhen Stock Exchange's guidelines for equity transfers [12][13]. - The inquiry transfer was conducted fairly and transparently, with 20 valid bids received from institutional investors [11][12].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688171 证券简称：纬德信息 公告编号：2025-036 广东纬德信息科技股份有限公司 股东询价转让定价情况提示性公告 股东魏秀君、广州纬腾投资合伙企业（有限合伙）、陈锐、张春（以下合称"出让方"）保证向广东纬德 信息科技股份有限公司（以下简称"纬德信息"或"公司"）提供的信息内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 （一）经向机构投资者询价后，初步确定的转让价格为28.99元/股。 （二）经出让方与组织券商协商，一致决定启动追加认购程序，追加认购截止时间不晚于2025年8月11 日。 二、风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被司法冻结、扣划等风险。询 价转让的最终结果以中国证券登记结算有限责任公司上海分公司最终办理结果为准。 （二）本次询价转让不涉及公司控制权变更，不会影响公司治理结构和持续经营。 特此公告。 广东纬德信息科技股份有限公司董事会 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 根据2025年7月3 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-054 科兴生物制药股份有限公司 ? 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 7 月 30 日，出让方所持公司股份数量、占总股本比 例情况如下： 序号 股东姓名 持股数量（股） 持股比例 （二）关于出让方是否为公司控股股东、实际控制人、持股 5%以上的股东、 董事、监事及高级管理人员 本次询价转让出让方科益医药持有公司股份比例超过 5%，为公司控股股东。 科益医药为公司实际控制人、董事长邓学勤控制的企业。 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 ...

Core Viewpoint - The shareholders of Guangdong Weide Information Technology Co., Ltd. plan to transfer a total of 3,350,936 shares, representing 4.00% of the company's total equity, through a pre-IPO inquiry transfer process [3][5]. Group 1: Shareholder Transfer Details - The shareholders involved in the transfer include Wei Xiujun, Guangzhou Weiteng Investment Partnership, Chen Rui, and Zhang Chun [3]. - Wei Xiujun intends to transfer 2,071,418 shares (2.47% of total equity), Weiteng Partnership 553,957 shares (0.66%), Chen Rui 394,612 shares (0.47%), and Zhang Chun 330,949 shares (0.40%) [3]. - The transfer will not occur through centralized bidding or block trading, and the shares acquired through this transfer cannot be sold within six months [3]. Group 2: Shareholder Background - None of the transferring shareholders are the controlling shareholders or actual controllers of Weide Information [4]. - Wei Xiujun is not a director or senior management of the company but serves as the executive partner of Weiteng Partnership, which holds over 5% of the shares collectively with Wei Xiujun and his concerted actors [4]. - Chen Rui and Zhang Chun are senior management members but do not hold more than 5% of the shares individually [4]. Group 3: Transfer Plan and Pricing - The total number of shares for transfer is 3,350,936, motivated by the shareholders' funding needs [5]. - The minimum transfer price will be set at no less than 70% of the average trading price over the 20 trading days prior to July 29, 2025 [6]. - If the total valid subscriptions exceed the number of shares available, the transfer price will be determined based on a priority system of price, quantity, and time [7]. Group 4: Investor Eligibility - The transfer is open to institutional investors with appropriate pricing capabilities and risk tolerance, including securities companies, fund management companies, and qualified foreign institutional investors [8][9]. - Other private fund managers registered with the Asset Management Association of China may also participate if their products are properly filed [9]. Group 5: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this transfer [9]. - There are no undisclosed significant matters affecting the company at this time [9].

Core Viewpoint - The company, Yuandong Biopharmaceutical Co., Ltd., is planning a non-public transfer of shares amounting to 3,369,550 shares, which represents 1.91% of its total share capital, to institutional investors through a pricing inquiry process [2][5]. Group 1: Share Transfer Details - The shareholders participating in the share transfer are Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership [2]. - The controlling shareholder and actual controller of the company will not participate in this share transfer, ensuring that their shares remain intact [2][3]. - The transfer is being organized by CITIC Securities, and the shares have been released from any restrictions, confirming clear ownership [3][4]. Group 2: Pricing and Transfer Conditions - The total number of shares to be transferred is 3,369,550, with the transfer price being set at a minimum of 70% of the average trading price over the 20 trading days prior to July 22, 2025 [5][6]. - The transfer process will prioritize price, quantity, and time of submission for determining the allocation of shares among interested institutional investors [7]. Group 3: Investor Eligibility - Eligible investors for this share transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [8]. Group 4: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this share transfer, and there are no other undisclosed significant matters [9].

Core Viewpoint - Shanghai Kai Bao Pharmaceutical Co., Ltd. has reduced its shareholding in Shanghai Yi Zhong Pharmaceutical Co., Ltd. from 11.95% to 10.95% through a block transfer of 2,067,037 shares at a price of 53.98 yuan per share, which constitutes a 1% change in equity [1][3][5]. Shareholding Changes - After the transfer, Shanghai Kai Bao will hold 1,047,642 shares, representing 0.99% of the total share capital of Shanghai Yi Zhong [2][4]. - Prior to the transfer, Shanghai Kai Bao's shareholding was 12.01% of the total share capital [2][3]. Transfer Details - The total share capital of Shanghai Yi Zhong is 143,888,000 shares after a capital increase [2][4]. - The transfer was conducted through an inquiry process, with 11 institutional investors submitting valid bids, resulting in 8 investors being allocated shares [7][8]. Regulatory Compliance - The transfer process adhered to relevant laws and regulations, ensuring fairness and compliance with market standards [8].

证券代码：688513 证券简称：苑东生物 公告编号：2025-050 成都苑东生物制药股份有限公司 股东询价转让计划书 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"公司"或"苑东生物"）提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ? 拟参与苑东生物首发前股东询价转让（以下简称"本次询价转让"）股东 为成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）； ? 公司控股股东、实际控制人直接或间接持有的股份不参与本次询价转让； ? 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2025-043 谱尼测试集团股份有限公司 股东询价转让计划书 宋薇、李阳谷、北京谱泰中瑞科技发展有限公司、北京谱瑞恒祥科技发展 有限公司保证向谱尼测试集团股份有限公司提供的信息内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律 责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 重要内容提示： "本公司"）首发前股东询价转让的股东为宋薇、李阳谷、北京谱泰中瑞科技发 展有限公司、北京谱瑞恒祥科技发展有限公司（以下合称"出让方"）； 级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转让； 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券股份有限公司（以下简称"中信证券"）组织实施谱尼测 试首发前股东询价转让（以下简称"本次询价转让"）。截至2025年7月21日，出让 方所持首发前股份的数量、占公司总股本比例情况如下： 序号 股东名称 持股数量（股） 持股占总股本比例 北京谱泰中瑞科技发展 有限公司 北京谱瑞恒祥科技发展 有限公司 （二）关 ...

Core Viewpoint - The company Kaisheng New Materials (301069.SZ) is planning a shareholder inquiry transfer of 20 million shares, representing 4.75% of its total share capital, primarily due to the financial needs of its major shareholder, Huabang Health (002004) [1][2]. Group 1: Shareholder Transfer Details - The total number of shares to be transferred by Huabang Health is 20,000,000, which constitutes 4.75% of Kaisheng New Materials' total share capital and 10.68% of Huabang Health's holdings [2]. - The transfer will not occur through centralized bidding or block trading, and the acquiring party must be an institutional investor with appropriate pricing and risk-bearing capabilities [2]. Group 2: Company Financials and Fundraising - Kaisheng New Materials raised a total of 310.20 million yuan from its initial public offering (IPO) in 2021, with a net amount of 281.89 million yuan, which was 26.81 million yuan less than originally planned [3]. - The company intended to raise 550 million yuan for various projects, including the expansion of a 20,000-ton aromatic polymer monomer facility and a 2,000-ton/year polyether ketone resin project [3]. - The total fundraising amount from two rounds of financing is 960.20 million yuan [5]. Group 3: Convertible Bond Issuance - Kaisheng New Materials has been approved to publicly issue convertible bonds totaling 650 million yuan, with each bond having a face value of 100 yuan [4]. - As of December 5, 2023, the company had issued 6.5 million convertible bonds, and the actual funds received amounted to approximately 639.73 million yuan after deducting underwriting fees [4].